Innate Pharma (IPHYF) Long-Term Deferred Tax (2018 - 2023)

Innate Pharma's Long-Term Deferred Tax history spans 6 years, with the latest figure at $9.7 million for Q4 2023.

  • For Q4 2023, Long-Term Deferred Tax rose 10.85% year-over-year to $9.7 million; the TTM value through Dec 2023 reached $9.7 million, up 10.85%, while the annual FY2023 figure was $9.7 million, 10.85% up from the prior year.
  • Long-Term Deferred Tax reached $9.7 million in Q4 2023 per IPHYF's latest filing, up from $8.7 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $9.7 million in Q4 2023 to a low of $1.4 million in Q4 2019.
  • Average Long-Term Deferred Tax over 5 years is $6.8 million, with a median of $8.4 million recorded in 2020.
  • Peak YoY movement for Long-Term Deferred Tax: skyrocketed 493.61% in 2020, then tumbled 31.93% in 2021.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $1.4 million in 2019, then surged by 493.61% to $8.4 million in 2020, then crashed by 31.93% to $5.8 million in 2021, then soared by 51.98% to $8.7 million in 2022, then rose by 10.85% to $9.7 million in 2023.
  • Per Business Quant, the three most recent readings for IPHYF's Long-Term Deferred Tax are $9.7 million (Q4 2023), $8.7 million (Q4 2022), and $5.8 million (Q4 2021).